TB-500

TB-500 traces back to thymosin beta-4, a small protein first identified in thymus tissue. Early work in the 1960s and 1970s isolated a mixture called thymosin fraction 5, and thymosin beta-4 was later characterized as one of the individual peptides within it. It is not exclusive to the thymus and is made in many tissues, and it shows up in high concentrations in wound fluid and platelets. A key clue to its role came from wound-healing research: scientists noticed that a particular protein appeared wherever tissue was injured, whether skin wounds, muscle damage, or inflammation, and that protein was thymosin beta-4. What stood out was that it did not only help tissue heal at the injury site, it seemed to help repair cells move through the body toward the damage. Researchers later pinpointed the active region responsible for much of that effect, and that shorter fragment is what is sold today as TB-500. It became widely known through veterinary use, particularly in racehorses, before it drew interest in human recovery circles.

TB-500 is read about most for stubborn tendon, ligament, and muscle injuries, but the underlying protein has been studied across a wider range of repair settings, including skin wounds, the surface of the eye, and heart tissue after injury. Its described jobs are to lower inflammation, limit scar tissue, and encourage new cells to grow where they are needed. It is also the peptide people most often pair with BPC-157, in what the community nicknamed the Wolverine stack. The two are described as complementary: BPC-157 is associated with new blood-vessel growth and better circulation to bring oxygen and nutrients to damaged tissue, while TB-500 is associated with moving repair cells in and driving regeneration. People who use it generally describe changes over weeks to months of consistent use rather than an overnight result.

Thymosin beta-4 is a 43 amino acid peptide, and its defining feature is that it binds actin, the internal scaffolding that lets a cell change shape and physically move. Repair and immune cells have to migrate quickly to the site of an injury, which means rapidly reorganizing that actin scaffolding. By supporting actin dynamics, thymosin beta-4 is described as helping those cells reach damaged tissue more efficiently, which is a first step in repair. It is also associated with the growth of new blood vessels, with lower inflammation, and with less fibrosis, meaning less thick scar tissue as a wound closes. Because it is a small and mobile molecule, it is generally described as distributing through the body rather than staying at one spot, which is part of why it is discussed for widespread or hard-to-reach injuries.

TB-500 is described in cited protocols as a subcutaneous injection rather than an oral product. Its small size is associated with good distribution through the body once administered, which fits the way people talk about it for systemic rather than purely local repair. This differs from BPC-157, where an oral form is often linked specifically to gut goals. This is background on how the compound is discussed, not a recommendation on route or dose.

The evidence picture has an important wrinkle worth understanding. Thymosin beta-4, the full parent protein, has been through formal human clinical trials, including work on dry eye and on slow-healing skin wounds. TB-500 as sold in the research-chemical market is usually described as a fragment or synthetic version of that protein, so the clinical trial results for thymosin beta-4 do not automatically transfer to it. Most of the direct evidence specific to TB-500 is from animal studies and from anecdotal reports. The honest summary is a well-studied parent protein with real human data, paired with a derived compound whose own formal human evidence is limited.

TB-500 has not been approved by the FDA. It is prohibited in sport by the World Anti-Doping Agency, which lists it among growth factors, and thymosin beta-4 has a well known history as a doping agent in horse racing, where it has featured in high-profile scandals, so athletes in tested sports should be aware of it. In late 2024 it was placed, alongside a number of other peptides, on an FDA list that restricts pharmacy compounding. Rules in this area are moving quickly, so treat any status as a snapshot in time.